Aprepitant-loaded solid lipid nanoparticles: a novel approach to enhance oral bioavailability

• Mazhar Hussain,
• Muhammad Farooq,
• Muhammad Asad Saeed,
• Muhammad Ijaz,
• Sherjeel Adnan,
• Zeeshan Masood,
• Muhammad Waqas,
• Wafa Ishaq and
• Nabeela Ameer

Beilstein J. Nanotechnol. 2025, 16, 652–663, doi:10.3762/bjnano.16.50

• . Therefore, the optimal SLN formulation APT-CD-NP4 is a promising tool for oral administration with sustained release to improve the bioavailability of the BCS class-IV drug APT. Keywords: aprepitant; β-cyclodextrin; pharmacokinetic study; poloxamer; solid lipid nanoparticles; Introduction Cancer is a

Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects

• Iqra Rahat,
• Pooja Yadav,
• Aditi Singhal,
• Mohammad Fareed,
• Jaganathan Raja Purushothaman,
• Mohammed Aslam,
• Raju Balaji,
• Sonali Patil-Shinde and
• Md. Rizwanullah

Beilstein J. Nanotechnol. 2024, 15, 1473–1497, doi:10.3762/bjnano.15.118

• -cPLHNPs represented higher cell uptake and antiproliferative activity against P388 cells than pure QCT. A pharmacokinetic study in SD rats suggested that the encapsulation of QCT in cPLHNPs improves the oral bioavailability of QCT by 3.75 times compared to pure QCT suspension. Further, an in vivo

Nanotechnological approaches for efficient N2B delivery: from small-molecule drugs to biopharmaceuticals

• Selin Akpinar Adscheid,
• Akif E. Türeli,
• Nazende Günday-Türeli and
• Marc Schneider

Beilstein J. Nanotechnol. 2024, 15, 1400–1414, doi:10.3762/bjnano.15.113

• administration. The optimization process yielded optimized NLCs with a particle size of 178 nm of and an entrapment efficiency of 77%. The in vivo pharmacokinetic study showed that intranasal administration of the optimized NLC formulation led to significantly faster drug absorption and greater clozapine

Fabrication of nanocrystal forms of ᴅ-cycloserine and their application for transdermal and enteric drug delivery systems

• Hsuan-Ang Tsai,
• Tsai-Miao Shih,
• Theodore Tsai,
• Jhe-Wei Hu,
• Yi-An Lai,
• Jui-Fu Hsiao and
• Guochuan Emil Tsai

Beilstein J. Nanotechnol. 2024, 15, 465–474, doi:10.3762/bjnano.15.42

• with methanol and then analyzed by LC-MS/MS. In vivo pharmacokinetic study of the enteric formulation The study protocol and the standard operating procedures (SOPs) were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Eurofins. All aspects of this study including

• , respectively. Other parameters require more detailed development experiments, and process analysis will be developed in the future. Rodent pharmacokinetic study for different crystal forms of DCS with oral formulation and enteric coating The findings of rat PK study, as shown in Table 5, revealed that DCS

Nanotechnological approaches in the treatment of schistosomiasis: an overview

• Lucas Carvalho,
• Michelle Sarcinelli and
• Beatriz Patrício

Beilstein J. Nanotechnol. 2024, 15, 13–25, doi:10.3762/bjnano.15.2

• encapsulating PZQ. They observed that the drug took more than one week in vitro to be released. A pharmacokinetic study in vivo also showed that the PZQ concentration in the plasma was sustained for longer times when the nanoformulation was studied in mice. Thus, the results show that solid lipid nanoparticles

Recognition mechanisms of hemoglobin particles by monocytes – CD163 may just be one

• Jonathan-Gabriel Nimz,
• Pichayut Rerkshanandana,
• Chiraphat Kloypan,
• Ulrich Kalus,
• Saranya Chaiwaree,
• Axel Pruß,
• Radostina Georgieva,
• Yu Xiong and
• Hans Bäumler

Beilstein J. Nanotechnol. 2023, 14, 1028–1040, doi:10.3762/bjnano.14.85

• when using HbMPs as oxygen carriers [34]. In addition to transporting oxygen, HbMPs can also be used as drug carriers. However, in a pharmacokinetic study with HbMPs, accumulation of the particles in the sinusoids of the liver, where the Kupffer cells are located, was observed [35]. The mechanisms of

Chitosan-based nanoparticles for improved anticancer efficacy and bioavailability of mifepristone

• Huijuan Zhang,
• Fuqiang Wu,
• Yazhen Li,
• Xiping Yang,
• Jiamei Huang,
• Tingting Lv,
• Yingying Zhang,
• Jianzhong Chen,
• Haijun Chen,
• Yu Gao,
• Guannan Liu and
• Lee Jia

Beilstein J. Nanotechnol. 2016, 7, 1861–1870, doi:10.3762/bjnano.7.178

• increased its efficacy by sustained release to reduce drug crystallization [33]. These results suggested that MCNs might be a good drug delivery system for delivery of MIF for cancer therapy. Pharmacokinetic study In our previous study, we found MIF showed distinct pharmacokinetic differences between

• genders. The bioavailability of MIF in male rats was significantly lower than in female rats [37]. Therefore, we chose male rats to perform the pharmacokinetic study to investigate whether MCNs could improve bioavailability of MIF. Following its oral administration, the plasma concentrations of MCNs were

• microplate reader. Pharmacokinetic study Animals Male Sprague-Dawley (SD) rats (180–220 g) were supplied by the Experimental Animal Center of Zhejiang Province and were housed with a 12 h dark/light cycle for three days before starting the experiment. The rats were fed a standard diet with water to drink ad